CABALETTA BIO, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
CABALETTA BIO, INC. (CABA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $47.13 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-23
- CABALETTA BIO, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $47.13M, a 23.49% increase from fiscal 2024.
- CABALETTA BIO, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $38.16M, a 66.86% increase from fiscal 2023.
- CABALETTA BIO, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $22.87M, a 169755.18% increase from fiscal 2022.
- CABALETTA BIO, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $13.46K, a 99.92% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $47.13M 10-K · filed 2026-03-23 |
| 2024-12-31 | $38.16M 10-K · filed 2025-03-31 |
| 2023-12-31 | $22.87M 10-K · filed 2024-03-21 |
| 2022-12-31 | $13.46K 10-K · filed 2023-03-16 |
| 2021-12-31 | $17.25M 10-K · filed 2022-03-17 |
| 2020-12-31 | $11.76M 10-K · filed 2021-03-16 |
| 2019-12-31 | $5.61M 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |